Department of Clinical Medicine, University of Copenhagen, Faculty of Health and Medical Sciences, Kobenhavn, Denmark
Early Psychosis Intervention Center, Psychiatric Services Region Zealand East, Roskilde, Denmark.
BMJ Open. 2021 Oct 7;11(10):e054308. doi: 10.1136/bmjopen-2021-054308.
The atypical antipsychotic clozapine has shown superior efficacy compared with other antipsychotics and is the gold standard for treating otherwise treatment resistant schizophrenia. However, multiple studies have found that clozapine is underutilised in most parts of the world. A few reviews of literature addressing barriers to clozapine prescribing have been conducted. While there is some variation in the literature included in these reviews, a common feature of the studies included is that they primarily focus on clinical staff's attitudes and perceived barriers for prescribing. Studies of patient perspectives are only sparsely included. A preliminary literature search revealed though, that additional literature on the subject exists, including literature on patient perspectives. It is therefore difficult to conclude if the formerly synthesised literature is representative of current evidence or if the topic has been adequately investigated to inform clinical practice. A scoping review is warranted in order to map and synthesise primary literature on patients' and psychiatrists' perspectives on clozapine treatment, and to identify gaps for future research.
The electronic databases Cochrane Library, CINAHL, Web of Science, Psychinfo, MEDLINE and EMBASE will be searched for relevant publications, supplied with searches of Google scholar, The Networked Digital Library of Theses and Dissertations and OpenGrey. Citation tracking of selected studies will furthermore be undertaken. Two researchers will independently screen and extract data. Data will be collated to provide a descriptive summary of the literature, along with a qualitative content analysis of key findings. Identified gaps in research will be accompanied by recommendations for future investigations.
Findings will be disseminated through a peer-reviewed journal and conference presentations. The scoping review does not require ethics approval.
与其他抗精神病药物相比，非典型抗精神病药氯氮平显示出更好的疗效，是治疗其他治疗抵抗性精神分裂症的金标准。然而，多项研究发现，氯氮平在世界上大多数地区的使用不足。已经有一些关于氯氮平处方障碍的文献综述。虽然这些综述中包含的文献有所不同，但纳入研究的一个共同特征是，它们主要关注临床工作人员的态度和开处方的感知障碍。只有很少的研究包括患者观点。尽管初步文献检索表明，关于这个主题的其他文献也存在，包括关于患者观点的文献。因此，很难确定以前综合的文献是否代表当前的证据，或者该主题是否已经得到充分研究，以告知临床实践。有必要进行范围界定审查，以绘制和综合患者和精神科医生对氯氮平治疗的看法的主要文献，并确定未来研究的空白。
将在 Cochrane 图书馆、CINAHL、Web of Science、Psychinfo、MEDLINE 和 EMBASE 电子数据库中搜索相关出版物，并辅以 Google Scholar、The Networked Digital Library of Theses and Dissertations 和 OpenGrey 的搜索。此外，还将对选定研究进行引文跟踪。两名研究人员将独立筛选和提取数据。将对数据进行整理，以提供文献的描述性摘要，并对关键发现进行定性内容分析。确定研究中的差距，并提出未来调查的建议。
研究结果将通过同行评议的期刊和会议报告进行传播。范围界定审查不需要伦理批准。
